Why Embark Technology Jumped Around 85%; Here Are 108 Biggest Movers From Friday
Gainers
Embark Technology, Inc. (NASDAQ: EMBK) jumped 84.8% to close at $1.07 on Friday after the company reported better-than-expected Q2 EPS results.
Why Twin Vee Powercats Is Trading Higher By Around 90%, Here Are 84 Stocks Moving In Friday’s Mid-Day Session
Gainers
Twin Vee Powercats Co. (NASDAQ: VEEE) shares jumped 90% to $7.60 after the company said Q2 sales results were up year over year.
LegalZoom.com, Toast And Some Other Big Stocks Moving Higher On Friday
Altimmune, Inc. (NASDAQ: ALT) jumped 28% to $17.64. B. Riley Securities maintained Altimmune with a Buy and raised the price target from $21 to $26.
12 Health Care Stocks Moving In Wednesday’s After-Market Session
Gainers
NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares increased by 15.1% to $0.63 during Wednesday's after-market session. The company's market cap stands at $16.7 million.
The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma’s Alzheimer’s Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral
Here's a roundup of top developments in the biotech space over the last 24 hours:
Piper Sandler Maintains Overweight on Day One Biopharmaceutical, Raises Price Target to $40
Piper Sandler analyst Joseph Catanzaro maintains Day One Biopharmaceutical (NASDAQ:DAWN) with a Overweight and raises the price target from $35 to $40.
Mid-Afternoon Market Update: Gold Down Over 2%; Electric Last Mile Solutions Shares Plummet
U.S. stocks traded lower toward the end of trading, with the S&P 500 dropping by more than 3% on Monday.
70 Stocks Moving In Monday’s Mid-Day Session
Gainers
Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares jumped 110% to $13.93 after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in relapsed pediatric low-grade glioma showed an overall response rate of 64%.
Why Day One Biopharma Shares Are Surging Today
Day One Biopharmaceuticals (NASDAQ: DAWN) shares are surging on initial data from the first 22 evaluable patients in the Phase 2 FIREFLY-1 trial for tovorafenib (DAY101) in relapsed or progressive pediatric low-grade glioma (pLGG), the most common brain tumor diagnosed in children.